Volrustomig for high-risk locally advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 15 or older and weigh more than 35 kg (about 77 lbs).
- You have been diagnosed with locally advanced cervical cancer that has not spread to other parts of the body.
- You have not already had a hysterectomy or a fertility-sparing procedure planned.
- You must be able to provide a tumor sample for testing.
- You cannot have a history of autoimmune disease, organ transplant, or another cancer in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding envafolimab (an immunotherapy medicine) to standard chemo and radiation improves outcomes for locally advanced cervical cancer. It may help your immune system better attack the cancer while you receive treatment aimed at cure or long-term control.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
This trial tests a new drug called volrustomig, alone or with other cancer treatments, for people with advanced or metastatic solid tumors. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug called volrustomig, which helps your immune system fight cancer, as a first treatment for advanced non-small cell lung cancer. It's for people whose tumors do not have certain gene changes (like EGFR) that have other targeted treatments available.
This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.